Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$103.20
-0.6%
$109.51
$77.56
$116.04
$25.10B0.682.26 million shs1.40 million shs
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$134.26
-0.9%
$129.09
$119.59
$146.85
$14.91B0.911.06 million shs601,724 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.38
+0.5%
$26.96
$25.20
$40.37
$143.72B0.6142.01 million shs46.48 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
+0.27%-2.07%-7.00%-1.79%+29.13%
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
-1.51%+7.58%+5.17%+3.85%-7.74%
Pfizer Inc. stock logo
PFE
Pfizer
-3.81%-0.49%-8.45%-8.03%-34.61%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
4.3567 of 5 stars
1.34.03.33.61.71.73.1
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
4.868 of 5 stars
2.13.04.24.73.72.52.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9742 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
2.55
Moderate Buy$103.07-0.12% Downside
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
2.25
Hold$146.178.87% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.16% Upside

Current Analyst Ratings

Latest DGX, CAH, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$138.00 ➝ $144.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$135.00 ➝ $145.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$139.00 ➝ $146.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$145.00 ➝ $150.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$150.00 ➝ $155.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/20/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$145.00
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/26/2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$205.01B0.12$8.66 per share11.92($11.20) per share-9.21
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$9.25B1.61$12.44 per share10.79$58.25 per share2.30
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.46$2.87 per share8.83$15.81 per share1.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$261M$2.5440.6312.961.000.30%-57.44%3.89%5/2/2024 (Confirmed)
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$854M$7.4318.0714.252.979.11%15.52%7.23%7/24/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.509.161.183.62%10.88%4.91%5/1/2024 (Confirmed)

Latest DGX, CAH, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$1.96N/A-$1.96N/AN/AN/A  
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/23/2024Q1 2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$1.86$2.04+$0.18$2.36$2.29 billion$2.37 billion      
2/1/2024Q2 2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$1.56$1.82+$0.26$2.21$57.02 billion$57.45 billion    
2/1/2024Q4 23
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.11$2.15+$0.04$2.60$2.25 billion$2.29 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$2.001.94%+1.00%78.74%27 Years
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.842.12%+8.08%38.22%13 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.62%+2.57%466.67%15 Years

Latest DGX, CAH, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/1/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
quarterly$0.752.34%4/5/20244/8/20244/22/2024
2/6/2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
quarterly$0.50061.92%3/28/20244/1/20244/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
N/A
0.98
0.50
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.59
0.97
1.20
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
87.17%
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
88.06%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
0.15%
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.79%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
48,000243.23 million242.87 millionOptionable
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
48,000111.06 million110.18 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

DGX, CAH, and PFE Headlines

SourceHeadline
Pfizer’s First Gene Therapy Gets Approval for Clotting DisorderPfizer’s First Gene Therapy Gets Approval for Clotting Disorder
bloomberg.com - April 26 at 10:34 PM
Pfizer (NYSE:PFE) Notches Up on New FDA ApprovalPfizer (NYSE:PFE) Notches Up on New FDA Approval
msn.com - April 26 at 10:34 PM
Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 26 at 9:14 PM
Pfizer (NYSE:PFE) Stock Price Up 0.3%Pfizer (NYSE:PFE) Stock Price Up 0.3%
marketbeat.com - April 26 at 5:58 PM
What Factors Will Drive Pfizers Q1 Performance?What Factors Will Drive Pfizer's Q1 Performance?
forbes.com - April 26 at 5:34 PM
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, UniqurePfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
finance.yahoo.com - April 26 at 5:34 PM
FDA Green Lights Pfizers Gene Therapy For Rare Bleeding Disorder HemophiliaFDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
finance.yahoo.com - April 26 at 5:34 PM
Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20
marketbeat.com - April 26 at 2:35 PM
GSK sues Pfizer and BioNTech over mRNA billionsGSK sues Pfizer and BioNTech over mRNA billions
thepharmaletter.com - April 26 at 12:33 PM
Pfizer Gains as Gene Therapy Wins FDA NodPfizer Gains as Gene Therapy Wins FDA Nod
baystreet.ca - April 26 at 12:33 PM
FDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia BFDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia B
thepharmaletter.com - April 26 at 12:33 PM
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key MetricsGear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com - April 26 at 10:21 AM
Pfizer Receives FDA Approval for Bleeding Disorder TreatmentPfizer Receives FDA Approval for Bleeding Disorder Treatment
barrons.com - April 26 at 9:35 AM
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 StocksWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
fool.com - April 26 at 7:45 AM
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia BPfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
marketwatch.com - April 26 at 7:33 AM
Pfizers Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia BPfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B
markets.businessinsider.com - April 26 at 7:33 AM
US FDA approves Pfizers gene therapy for rare bleeding disorderUS FDA approves Pfizer's gene therapy for rare bleeding disorder
reuters.com - April 26 at 7:33 AM
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
finance.yahoo.com - April 26 at 7:33 AM
Pfizer Now Rivals The Worlds Most Expensive Medicine After FDA Approves Gene TherapyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
finance.yahoo.com - April 26 at 7:33 AM
UPDATE 2-US FDA approves Pfizers gene therapy for rare bleeding disorderUPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder
finance.yahoo.com - April 26 at 7:33 AM
FDA approves Pfizers first gene therapy for rare inherited bleeding disorderFDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
cnbc.com - April 26 at 7:02 AM
U.S. FDA Approves Pfizers BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
businesswire.com - April 26 at 6:45 AM
Pfizer (NYSE:PFE) Trading Down 2.5%Pfizer (NYSE:PFE) Trading Down 2.5%
marketbeat.com - April 25 at 6:18 PM
Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 25 at 5:33 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cardinal Health logo

Cardinal Health

NYSE:CAH
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Quest Diagnostics logo

Quest Diagnostics

NYSE:DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.